Prostate cancer: AR splice variant dimerization - Clinical implications

Nature Reviews Urology

Volumn 12, Issue 8, 2015, Pages 431-433

  Antonarakis, Emmanuel S ^a   Luo, Jun ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE; ANDROGEN RECEPTOR; DNA BINDING PROTEIN; ENZALUTAMIDE; MESSENGER RNA; ISOPROTEIN;

CANCER HORMONE THERAPY; CARBOXY TERMINAL SEQUENCE; CASTRATION RESISTANT PROSTATE CANCER; DIMERIZATION; HUMAN; PRIORITY JOURNAL; SHORT SURVEY; TRANSCRIPTION INITIATION; GENETICS; MALE;

HUMANS; MALE; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; PROTEIN ISOFORMS; RECEPTORS, ANDROGEN;

EID: 84938928670     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2015.184     Document Type: Short Survey

References (10)

1. Xu, D. et al. Androgen receptor splice variants dimerize to transactivate target genes. Cancer Res. http://dx.doi.org/10.1158/ 0008-5472CAN-15-0381.
2. Antonarakis, E. S. et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N. Engl. J. Med. 371, 1028-1038 (2014).
3. Steinestel, J. et al. Detecting predictive androgen receptor modifications in circulating prostate cancer cells. Oncotarget (in press).
4. Cao, B. et al. Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy. Oncotarget 5, 1646-1656 (2014).
5. Tepper, C. G. et al. Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line. Cancer Res. 62, 6606-6614 (2002).
6. Yang, L. et al. lncRNA-dependent mechanisms of androgen-receptor-regulated gene activation programs. Nature 500, 598-602 (2013).
7. Antonarakis, E. S. et al. Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer. JAMA Oncol. http://dx.doi.org/10.1001/ jamaoncol.2015.1341.
8. Purushottamachar, P. et al. Systematic structure modifications of multitarget prostate cancer drug candidate galeterone to produce novel androgen receptor down-regulating agents as an approach to treatment of advanced prostate cancer. J. Med. Chem. 56, 4880-4898 (2013).
9. Myung, J. K. et al. An androgen receptor N-terminal domain antagonist for treating prostate cancer. J. Clin. Invest. 123, 2948-2960 (2013).
10. Asangani, I. A. et al. Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Nature 510, 278-282 (2014).